ClinicalTrials.gg
Active, not recruitingNCT04434092COMMODORE 2Updated Oct 26, 2026Results posted

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

A Phase 3 interventional study of Crovalimab and Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Hoffmann-La Roche. Active, not recruiting at 63 sites in 23 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Hemoglobinuria, Paroxysmal with a site in Spain — 3 open to participants now, 8 under way, 6 of them phase 3. Hemoglobinuria, Paroxysmal · Spain.

Enrollment
2nd of 23
210 · median 85
Started
2020
with 2 others
Phase 3
17 of 24
2 open now
Registered
11th of 24
by date
Lead sponsor
2 of 24
Hoffmann-La Roche

Among the 24 studies in Hemoglobinuria, Paroxysmal with a site in Spain, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2020, is one of 17 in phase 3, and was the 11th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 24 studies in Hemoglobinuria, Paroxysmal with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hemoglobinuria, Paroxysmal with a site in Spain, or all of them as a file.
02

Study summary

A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH who have not been previously treated with complement inhibitor therapy.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight ≥ 40 kg at screening (pediatric participants with body weight \< 40 kg)
  • Willingness and ability to comply with all study visits and procedures
  • Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry
  • LDH level ≥ 2x at screening (as per local assessment)
  • Vaccination against Neisseria meningitidis serotypes A, C, W, and Y\< 3 years prior to initiation of study treatment; or, if not previously done, vaccination administered no later than one week after the first drug administration
  • Women of : agreement to remain abstinent or use during the treatment period and for 10.5 months after the final dose of crovalimab or for 3 months after the final dose of eculizumab (or longer if required by the local product label)

Exclusion criteria

Exclusion Criteria:

  • Current or previous treatment with a complement inhibitor
  • History of bone marrow transplantation
  • History of Neisseria meningitidis infection within 6 months prior to screening and up to first study drug administration
  • History of myelodysplastic syndrome with Revised International Prognostic Scoring System (IPSS-R) prognostic risk categories of intermediate, high and very high
  • Pregnant or breastfeeding, or intending to become pregnant during the study, within 10.5 months after the final dose of crovalimab, or 3 months after the final dose of eculizumab (or longer if required by the local product label)
  • Participation in another interventional treatment study with an agent or use of any experimental therapy within 28 days of screening or within 5 half-lives of that investigational product, whichever is greater
  • Concurrent disease, treatment, procedure or surgery, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the participant, or would, in the opinion of the Investigator, preclude the participant's safe participation in and completion of the study
  • Splenectomy \< 6 months before screening
  • Positive for Active and C infection (HBV/)
  • History of or ongoing cryoglobulinemia at screening
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    Arm A (Crovalimab)

    Crovalimab will be administered at an initial loading dose of 1000 milligrams (mg) (for participants with body weight between 40 and 100 kilograms \[kg\]) or 1500 mg (for participants with body weight ≥ 100 kg), as intravenous (IV) injection on Day 1 of Week 1 followed by four weekly subcutaneous (SC) injections of 340 mg starting on Day 2 of Week 1 and then once weekly (QW) at Weeks 2,3 and 4. Thereafter crovalimab will be administered, as SC injection, at a maintenance dose of 680 mg (for participants with body weight between 40 and 100 kg) or 1020 mg (for participants with body weight ≥ 100 kg) once every 4 weeks (Q4W) from Week 5 for a total of 24 weeks of study treatment. Participants may continue to receive crovalimab after 24 weeks of treatment up to maximum of 5 years.

    Drug: Crovalimab

  • Active comparator
    Arm B (Eculizumab)

    Participants will receive loading dose of eculizumab 600 mg on Days 1, 8, 15, and 22, followed by maintenance dose of 900 mg on Day 29 and every 2 weeks (Q2W) thereafter until 24 weeks. Participants may switch to receive crovalimab after 24 weeks of eculizumab treatment.

    Drug: Crovalimab · Drug: Eculizumab

  • Experimental
    Arm C (Crovalimab) (Exploratory)

    Participants with a body weight ≥ 5 to \<12 kg will receive a loading series of crovalimab doses comprised of an IV dose on Day 1 of Week 1, followed by crovalimab SC dose on Day 2 Week 1. Maintenance doses will begin at Week 3 and will be administered Q2W, thereafter. Participants with a body weight ≥ 12 to \< 20 kg and ≥ 20 kg will receive a loading series of crovalimab doses comprised of an IV dose on Day 1 of Week 1, followed by weekly crovalimab SC doses for 4 weeks at Week 1 (Day 2) and then at Weeks 2, 3, and 4. Maintenance doses will begin at Week 5 and will be administered Q2W thereafter, for participants with a body weight ≥ 12 to \< 20 kg and Q4W thereafter, for participants with a body weight \> 20 kg. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab.

    Drug: Crovalimab

Interventions

  • Dosing depends on body weight. Participants will be dosed as follows: * 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study * 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study * 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study * 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study * 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study * 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study.

  • Eculizumab will be administered as specified in the respective arm.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Transfusion Avoidance (TA)

    TA is defined as participants who are packed red blood cell (pRBC) transfusion-free and do not require transfusion per protocol-specified guidelines. 95% Confidence Interval (CI) for percentage of participants with TA was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to have had a transfusion. Percentages are rounded off to the nearest single decimal.

    Time frame: Baseline to Week 25

  2. Percentage of Participants With Hemolysis Control Measured by LDH

    A Generalized Estimating Equation (GEE) was used to estimate the population-average percentage of the participants with hemolysis control (measured by LDH ≤1.5 x upper limit of normal (ULN)) from Week 5 to Week 25 taking account of the intra-patient and inter-patient correlation between LDH control statuses across visits. Percentages are rounded off to the nearest single decimal.

    Time frame: Week 5 to Week 25

Secondary outcomes

  1. Percentage of Participants With Breakthrough Hemolysis (BTH)

    BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \< 10 grams per deciliter (g/dL)\], major adverse vascular event \[MAVE, including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2xULN after a prior LDH reduction to ≤1.5xULN from the start of study treatment. 95% CI for percentage of participants with BTH was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to have experienced a BTH event. Percentages are rounded off to the nearest single decimal.

    Time frame: Baseline to Week 25

  2. Percentage of Participants With Stabilization of Hemoglobin

    Stabilized hemoglobin is defined as avoidance of a \>= 2 g/dL decrease in hemoglobin level from baseline, in the absence of transfusion. 95% CI for percentage of participants with stabilized hemoglobin was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to not have had hemoglobin stabilization. Percentages are rounded off to the nearest single decimal.

    Time frame: Baseline to Week 25

  3. Change From Baseline in Fatigue Assessed by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale

    Fatigue was assessed using FACIT-F scale. FACIT-F is a self-assessment questionnaire with a 7-day recall period and 13 items evaluating fatigue and its impact on daily life activities. Items are scored on a response scale that ranges from 0 ("not at all") to 4 ("very much so"). Relevant items are reverse scored, and all the items are summed to create a total score range from 0 to 52, with 0 being the worst possible score and 52 being the best possible score. A higher score indicates low fatigue severity. A positive mean change indicates improvement. FACIT-F was assessed in adult participants only.

    Time frame: Baseline to Week 25

  4. Percentage of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs are reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.

    Time frame: Up to 6 years

  5. Percentage of Participants With Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity and Infections (Including Meningococcal Meningitis)

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Injection-site reactions or infusion-related reaction are AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.

    Time frame: Up to 6 years

  6. Percentage of Participants With AEs Leading to Study Drug Discontinuation

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs are reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.

    Time frame: Up to 6 years

  7. Percentage of Participants With Clinical Manifestations of Drug-Target-Drug Complex (DTDC) Formation Amongst Participants Who Switched to Crovalimab Treatment From Eculizumab Treatment

    Time frame: Up to 6 years

  8. Serum Concentrations of Crovalimab And Eculizumab Over Time

    Time frame: Up to 6 years

  9. Percentage of Participants With Anti-Crovalimab Antibodies

    Time frame: Up to 6 years

  10. Change in Pharmacodynamic (PD) Biomarkers Including Complement Activity (CH50) Over Time

    Time frame: Up to 6 years

  11. Change Over Time in Free C5 Concentration in Crovalimab-Treated Participants

    Time frame: Up to 6 years

  12. Observed Value in Reticulocyte Count (Count/Milliliters [mL])

    Time frame: Up to 6 years

  13. Observed Value in Haptoglobin (Milligrams Per Deciliter [mg/dL])

    Time frame: Up to 6 years

  14. Change From Baseline in Absolute Reticulocyte Count

    Time frame: Baseline, Day 1 Week 1, Week 2, 3, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25

  15. Change From Baseline in Free Hemoglobin

    Time frame: Baseline, Week 2, 3, 4, 5, 9, 13, 17, 21, and 25

  16. Change From Baseline in Haptoglobin

    Time frame: Baseline, Week 2, 3, 4, 5, 9, 13, 15, 17, 21, and 25

07

Results

Posted Nov 10, 2025

Participant flow

Participants were enrolled at centres in Argentina, Brazil, China, France, Greece, Germany, Hong Kong, Japan, Lithuania, Malaysia, Mexico, Netherlands, Philippines, Poland, Portugal, Romania Republic of Korea, Singapore, Spain, Sweden, Thailand, Türkiye, Taiwan, Ukraine, and United Kingdom from 08 Oct 2020 to 16 Nov 2022. The study is ongoing.

Primary Treatment Period:Baseline-Week24
Participant flow — Primary Treatment Period:Baseline-Week24
MilestoneArm A: CrovalimabArm B: EculizumabArm C: Crovalimab
Started135696
Completed129686
Not completed610
Withdrew: Physician decision200
Withdrew: Withdrawal by subject200
Withdrew: Lost to follow-up100
Withdrew: Death110
Extension Treatment Period:Week 25-5 Yrs
Participant flow — Extension Treatment Period:Week 25-5 Yrs
MilestoneArm A: CrovalimabArm B: EculizumabArm C: Crovalimab
Started129686
Completed000
Not completed129686
Withdrew: Treatment (crovalimab) ongoing127656
Withdrew: Withdrawal by subject220
Withdrew: Adverse event010

Outcome measures

PrimaryPercentage of Participants With Transfusion Avoidance (TA)

TA is defined as participants who are packed red blood cell (pRBC) transfusion-free and do not require transfusion per protocol-specified guidelines. 95% Confidence Interval (CI) for percentage of participants with TA was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to have had a transfusion. Percentages are rounded off to the nearest single decimal.

Time frame:
Baseline to Week 25
Reported as:
Number · percentage of participants
Percentage of Participants With Transfusion Avoidance (TA)
percentage of participantsArm A: CrovalimabArm B: Eculizumab
Percentage of Participants With Transfusion Avoidance (TA)65.7 (56.91 to 73.52)68.1 (55.67 to 78.53)
Statistical analysis
  • Arm A: Crovalimab vs Arm B: Eculizumab · Weighted difference in proportion: -2.8 · 95% CI -15.67 to 11.1495% CI for the difference in proportions of participants with TA is calculated by Stratified Newcombe CI method.
PrimaryPercentage of Participants With Hemolysis Control Measured by LDH

A Generalized Estimating Equation (GEE) was used to estimate the population-average percentage of the participants with hemolysis control (measured by LDH ≤1.5 x upper limit of normal (ULN)) from Week 5 to Week 25 taking account of the intra-patient and inter-patient correlation between LDH control statuses across visits. Percentages are rounded off to the nearest single decimal.

Time frame:
Week 5 to Week 25
Reported as:
Number · percentage of participants
Percentage of Participants With Hemolysis Control Measured by LDH
percentage of participantsArm A: CrovalimabArm B: Eculizumab
Percentage of Participants With Hemolysis Control Measured by LDH79.3 (72.86 to 84.48)79.0 (69.66 to 85.99)
Statistical analysis
  • Arm A: Crovalimab vs Arm B: Eculizumab · Odds ratio (or): 1.02 · 95% CI 0.57 to 1.82
SecondaryPercentage of Participants With Breakthrough Hemolysis (BTH)

BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \< 10 grams per deciliter (g/dL)\], major adverse vascular event \[MAVE, including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2xULN after a prior LDH reduction to ≤1.5xULN from the start of study treatment. 95% CI for percentage of participants with BTH was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to have experienced a BTH event. Percentages are rounded off to the nearest single decimal.

Time frame:
Baseline to Week 25
Reported as:
Number · percentage of participants
Percentage of Participants With Breakthrough Hemolysis (BTH)
percentage of participantsArm A: CrovalimabArm B: Eculizumab
Percentage of Participants With Breakthrough Hemolysis (BTH)10.4 (6.04 to 17.21)14.5 (7.54 to 25.50)
Statistical analysis
  • Arm A: Crovalimab vs Arm B: Eculizumab · Weighted difference in proportion: -3.9 · 95% CI -14.82 to 5.2695% CI for the difference in proportions of participants is calculated by Stratified Newcombe CI method.
SecondaryPercentage of Participants With Stabilization of Hemoglobin

Stabilized hemoglobin is defined as avoidance of a \>= 2 g/dL decrease in hemoglobin level from baseline, in the absence of transfusion. 95% CI for percentage of participants with stabilized hemoglobin was calculated using the Wilson's method with continuity correction. Participants who withdrew before Week 25 were deemed to not have had hemoglobin stabilization. Percentages are rounded off to the nearest single decimal.

Time frame:
Baseline to Week 25
Reported as:
Number · percentage of participants
Percentage of Participants With Stabilization of Hemoglobin
percentage of participantsArm A: CrovalimabArm B: Eculizumab
Percentage of Participants With Stabilization of Hemoglobin63.4 (54.63 to 71.45)60.9 (48.35 to 72.17)
Statistical analysis
  • Arm A: Crovalimab vs Arm B: Eculizumab · Weighted difference in proportion: 2.2 · 95% CI -11.37 to 16.3195% CI for the difference in proportions of participants is calculated by Stratified Newcombe CI method.
SecondaryChange From Baseline in Fatigue Assessed by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale

Fatigue was assessed using FACIT-F scale. FACIT-F is a self-assessment questionnaire with a 7-day recall period and 13 items evaluating fatigue and its impact on daily life activities. Items are scored on a response scale that ranges from 0 ("not at all") to 4 ("very much so"). Relevant items are reverse scored, and all the items are summed to create a total score range from 0 to 52, with 0 being the worst possible score and 52 being the best possible score. A higher score indicates low fatigue severity. A positive mean change indicates improvement. FACIT-F was assessed in adult participants only.

Time frame:
Baseline to Week 25
Reported as:
Mean · score on scale
Change From Baseline in Fatigue Assessed by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale
score on scaleArm A: CrovalimabArm B: Eculizumab
Baseline36.02 ± 0.87735.09 ± 1.408
Change at Week 257.79 ± 0.6615.15 ± 0.880
Statistical analysis
  • Arm A: Crovalimab vs Arm B: Eculizumab · Difference in adjusted mean: 2.64 · 95% CI 0.68 to 4.60Non-inferiority is met when the lower limit of the 95% CI is greater than -5.
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs are reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.

Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity and Infections (Including Meningococcal Meningitis)

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Injection-site reactions or infusion-related reaction are AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.

Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With AEs Leading to Study Drug Discontinuation

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs are reported based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0.

Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Clinical Manifestations of Drug-Target-Drug Complex (DTDC) Formation Amongst Participants Who Switched to Crovalimab Treatment From Eculizumab Treatment
Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondarySerum Concentrations of Crovalimab And Eculizumab Over Time
Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Anti-Crovalimab Antibodies
Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondaryChange in Pharmacodynamic (PD) Biomarkers Including Complement Activity (CH50) Over Time
Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondaryChange Over Time in Free C5 Concentration in Crovalimab-Treated Participants
Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondaryObserved Value in Reticulocyte Count (Count/Milliliters [mL])
Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondaryObserved Value in Haptoglobin (Milligrams Per Deciliter [mg/dL])
Time frame:
Up to 6 years

Results for this outcome have not been posted.

SecondaryChange From Baseline in Absolute Reticulocyte Count
Time frame:
Baseline, Day 1 Week 1, Week 2, 3, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25
Reported as:
Mean · 10^9 cells/liter (L)
Change From Baseline in Absolute Reticulocyte Count
10^9 cells/liter (L)Arm A: CrovalimabArm B: Eculizumab
Baseline2865.56 ± 22637.24164.26 ± 114.27
Change at Week 1 Day 1-58.50 ± NA—
Change at Week 2542.90 ± 4314.07105.88 ± 601.77
Change at Week 3-71.08 ± 533.01-15.62 ± 53.79
Change at Week 48.52 ± 58.01-10.56 ± 51.36
Change at Week 5-1126.63 ± 9074.194.85 ± 49.43
Change at Week 7-3517.66 ± 26606.217020.33 ± 38344.72
Change at Week 912.60 ± 62.0520.65 ± 60.04
Change at Week 11425.66 ± 3343.9926.12 ± 81.80
Change at Week 1324.47 ± 48.9228.61 ± 78.48
Change at Week 15-838.52 ± 6735.1337.20 ± 77.52
Change at Week 171929.82 ± 15576.3733.22 ± 73.34
Change at Week 1962.91 ± 390.3922.16 ± 70.68
Change at Week 21633.95 ± 4919.9715.90 ± 72.72
Change at Week 23698.79 ± 5409.0527.51 ± 85.87
Change at Week 251396.46 ± 11622.5732.31 ± 97.79
SecondaryChange From Baseline in Free Hemoglobin
Time frame:
Baseline, Week 2, 3, 4, 5, 9, 13, 17, 21, and 25
Reported as:
Mean · milligram per litre (mg)/L
Change From Baseline in Free Hemoglobin
milligram per litre (mg)/LArm A: CrovalimabArm B: Eculizumab
Baseline474.88 ± 276.49495.69 ± 393.56
Change at Week 2-406.39 ± 273.33-407.10 ± 339.84
Change at Week 3-409.10 ± 286.35-393.20 ± 352.22
Change at Week 4-413.16 ± 281.40-418.00 ± 441.01
Change at Week 5-386.62 ± 424.67-421.14 ± 402.64
Change at Week 9-404.29 ± 298.64-405.89 ± 425.73
Change at Week 13-409.94 ± 298.14-328.56 ± 586.25
Change at Week 17-408.15 ± 285.24-340.00 ± 503.24
Change at Week 21-367.86 ± 341.53-387.63 ± 462.10
Change at Week 25-431.50 ± 277.83-334.96 ± 516.40
SecondaryChange From Baseline in Haptoglobin
Time frame:
Baseline, Week 2, 3, 4, 5, 9, 13, 15, 17, 21, and 25
Reported as:
Mean · gram (g)/L
Change From Baseline in Haptoglobin
gram (g)/LArm A: CrovalimabArm B: Eculizumab
Baseline0.05 ± 0.000.05 ± 0.00
Change at Week 20.05 ± 0.140.08 ± 0.19
Change at Week 30.05 ± 0.160.11 ± 0.28
Change at Week 40.08 ± 0.210.12 ± 0.28
Change at Week 50.06 ± 0.160.09 ± 0.23
Change at Week 90.05 ± 0.170.07 ± 0.23
Change at Week 130.04 ± 0.170.06 ± 0.21
Change at Week 170.05 ± 0.160.05 ± 0.14
Change at Week 210.06 ± 0.180.06 ± 0.22
Change at Week 250.06 ± 0.170.05 ± 0.21

Adverse events

Collected over From randomization until primary completion date cutoff (up to approximately 25 weeks) Data collected up to 25 weeks are reported here. Adverse event data collection for the Extension Treatment Period is ongoing and will be reported one year after the study completion date.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Crovalimab2/135 (1.5%)22/135 (16.3%)102/135 (75.6%)
Arm B: Eculizumab1/69 (1.4%)14/69 (20.3%)55/69 (79.7%)
Arm C: Crovalimab0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventArm A: CrovalimabArm B: EculizumabArm C: Crovalimab
PneumoniaInfections and infestations4/1350/690/6
Aplastic anaemiaBlood and lymphatic system disorders2/1351/690/6
Upper respiratory tract infectionInfections and infestations2/1350/690/6
EpistaxisRespiratory, thoracic and mediastinal disorders2/1350/690/6
AnaemiaBlood and lymphatic system disorders0/1351/690/6
Febrile neutropeniaBlood and lymphatic system disorders0/1351/690/6
ThrombocytopeniaBlood and lymphatic system disorders1/1351/690/6
Cardiac failureCardiac disorders0/1351/690/6
PyrexiaGeneral disorders1/1351/690/6
Cholecystitis chronicHepatobiliary disorders0/1351/690/6
Most frequent other events
Showing 10 of 22
Most frequent other events
EventArm A: CrovalimabArm B: EculizumabArm C: Crovalimab
HyperuricaemiaMetabolism and nutrition disorders11/1357/692/6
COVID-19Infections and infestations28/1359/690/6
Aphthous ulcerGastrointestinal disorders0/1350/691/6
FatigueGeneral disorders4/1353/691/6
PyrexiaGeneral disorders15/1358/691/6
Urinary tract infectionInfections and infestations5/1355/691/6
ContusionInjury, poisoning and procedural complications2/1351/691/6
HypocalcaemiaMetabolism and nutrition disorders8/1357/691/6
HypokalaemiaMetabolism and nutrition disorders15/1359/691/6
HypomagnesaemiaMetabolism and nutrition disorders3/1351/691/6

Baseline characteristics

All Participant Population includes all participant enrolled to the originally assigned treatment arms (Arms A, B and C).

Age, Categorical
Age, Categorical(Participants)Arm A: CrovalimabArm B: EculizumabArm C: CrovalimabTotal
<=18 years0268
Between 18 and 65 years122580180
>=65 years139022
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: CrovalimabArm B: EculizumabArm C: CrovalimabTotal
Female5834294
Male77354116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: CrovalimabArm B: EculizumabArm C: CrovalimabTotal
Hispanic or Latino186125
Not Hispanic or Latino114615180
Unknown or Not Reported3205
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: CrovalimabArm B: EculizumabArm C: CrovalimabTotal
American Indian or Alaska Native0000
Asian86515142
Native Hawaiian or Other Pacific Islander0000
Black or African American3104
White4516061
More than one race0000
Unknown or Not Reported1113
08

Study locations

63 sites
09

References and documents

Publications

  • Tong H, Lin Z, Yang C, Wang X, Sun J, Xia L, Shi J, Shi D, Zhang Z, Appius A, He G. Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study. Ann Hematol. 2026 Jun 13. doi: 10.1007/s00277-026-07129-3. Online ahead of print. PubMed 42287326 ↗
  • Kulasekararaj AG, Nishimura JI, Roth A, Beveridge L, Buatois S, Buri M, Compagno N, Luder Y, Sreckovic S, Scheinberg P. Managing transient immune complex reactions in patients with paroxysmal nocturnal hemoglobinuria: clinical observations from the COMMODORE 1 and 2 studies. Ther Adv Hematol. 2025 Sep 17;16:20406207251359246. doi: 10.1177/20406207251359246. eCollection 2025. PubMed 40978458 ↗
  • Roth A, Fu R, He G, Alzahrani H, Chou SC, Hicheri Y, Kazmierczak M, Recova VL, Uchiyama M, Vladareanu AM, Beveridge L, Buatois S, Buri M, Compagno N, Shi D, Balachandran N, Sreckovic S, Scheinberg P. Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies. Eur J Haematol. 2025 Feb;114(2):373-382. doi: 10.1111/ejh.14339. Epub 2024 Nov 13. PubMed 39535306 ↗
  • Roth A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, Lee JH, Brodsky A, Hantaweepant C, Dumagay TE, Demichelis-Gomez R, Rojnuckarin P, Sun J, Hoglund M, Jang JH, Gaya A, Silva F, Obara N, Kelly RJ, Beveridge L, Buatois S, Chebon S, Gentile B, Lundberg P, Sreckovic S, Nishimura JI, Risitano A, Han B. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. Am J Hematol. 2024 Sep;99(9):1768-1777. doi: 10.1002/ajh.27412. Epub 2024 Jun 17. PubMed 38884175 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Nov 2022, 25 months.

Results were first posted in Nov 2025, 2 years 11 months after primary completion. A results delay was requested in Nov 2023.

Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 25 months is close to that.

Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2020
First posted
Jun 16, 2020
StartActual
Oct 8, 2020
Primary completionActual
Nov 16, 2022
CompletionEst.
Apr 18, 2027
Results delay requested
Nov 15, 2023
Results first posted
Nov 10, 2025
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04434092
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 16, 2020
Start date
Oct 8, 2020
Primary completion
Nov 16, 2022
Completion
Apr 18, 2027 (estimated)
Results posted
Nov 10, 2025
Last update
Oct 26, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Crovalimab

Start the discussion